Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Lantern Pharma Touts Encouraging Positive Efficacy For Pancreatic Cancer Candidate

Published 14/09/2022, 17:05
© Reuters.  Lantern Pharma Touts Encouraging Positive Efficacy For Pancreatic Cancer Candidate
LTRN
-

  • Lantern Pharma Inc (NASDAQ: LTRN) will present preclinical data on the in vivo efficacy of its drug candidate LP-184 for pancreatic cancer at the American Association for Cancer Research Special Conference.
  • LP-184 is a small molecule drug candidate and next-generation acylfulvene that preferentially damages DNA in cancer cells harboring mutations in DNA damage repair (DDR) genes and overexpressing the enzyme PTGR1.
  • Pancreatic cancer cells are expected to be sensitive to LP-184 treatment, as around 25% of these cancers harbor elevated levels of PTGR1 and mutations in DDR genes.
  • After two rounds of LP-184 treatment, the ATR and BRCA1 pancreatic cancer mouse models had tumor growth inhibitions of 140% and 112%, respectively. LP-184 treatment was generally well-tolerated in these mice, and minimal differences were observed in body weight and blood counts relative to treatment control groups.
  • The AACR presentation will show additional data demonstrating that LP-184 can act synergistically in vitro and in vivo with several standard-of-care or FDA-approved agents.
  • These results demonstrate LP-184's potential as a therapeutic agent for pancreatic cancer as a monotherapy or combination with other approved therapies.
  • The company expects a targeted IND submission for LP-184 in Q1 2023 and Phase 1 clinical trials to commence in Q2 2023.
  • Price Action: LTRN shares are up 9.09% at $5.52 on the last check Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.